WELCOME
Norovirus
NOROVIRUS
Norovirus is the leading cause of infectious gastroenteritis in developed countries worldwide. Outbreaks of the virus are very common in long-term care facilities, hospitals and schools, and complications related to the infection can include organ dysfunction or even death. LigoCyte has developed a first-in-class VLP vaccine against norovirus that is currently undergoing human testing.
Read More
Influenza
INFLUENZA
Influenza is a common virus that causes respiratory infections. Each year in the United States, up to one-fifth of the population is infected with influenza, leading to more than 200,000 hospitalizations and 36,000 deaths. LigoCyte’s VLP vaccine against influenza has demonstrated a high degree of protection in disease models.
Read More
Ligocyte Office
COMPANY
LigoCyte is a clinical-stage biologic drug development company focused on respiratory and gastrointestinal indications. The company’s virus-like particle (VLP) vaccine technologies support products that induce robust immune responses to prevent serious infections.
Read More
News Icon

LIGOCYTE PHARMACEUTICALS FINALIZES AGREEMENT FOR $28M SERIES “C” FINANCING ROUND
Thu, 10 Jul 2008 1:30:16 GMT, Source LigoCyte Pharmaceuricals

Two Die as Deadly Virus Hits Hospital
New Zealand Herald, New Zealand - Oct 15, 2008

Norovirus Blamed in Outbreak at Georgetown University
Washington Post, United States - Oct 2, 2008